Index

5Max reperfusion catheter  141
duration of therapy  94–95
future directions  96–97
in ACS, PCI and STEMI interventions  81–91
monotherapy (without aspirin)  96
newer agents  85–91
nonprimary percutaneous coronary intervention  92
older agents  81–85
oral absorption in STEMI  92–93
physiology  75–80
platelets and coagulation  76
potential reversal strategies  96–97
STEMI and the pro-thrombotic state  75
steps in the coagulation process  76
use with oral anticoagulants  95

ADMIRAL trial  189
Air-PAMI trial  300, 301
Alexander, Thomas  364
ALKK-PCI registry  25
alteplase  56
American College of Cardiology (ACC) guidelines  35–48, 318, 398–399
American College of Cardiology Foundation (ACCF)  35
American Heart Association (AHA) guidelines  35–48, 318, 398–399
angiography, guidelines for patients with chronic kidney disease  45
AngioJet® thrombectomy device  126–130, 141, 172, 173, 175, 182, 223
anorexic encephalography  295
anticoagulant therapy  56–57
guidelines for STEMI  46

abciximab  46, 60–61, 70, 80, 189
Absorb™ bioresorbable vascular scaffold (BVS)  202
ABSORB II trial  415, 416
ACCESS registry  363
ACCOAST trial  86, 87
ACTION Registry–GWTG database analyses  290, 291–292
ACUITY trial  148
acute circulatory support in STEMI  107–115
effects of myocardial reperfusion  107
goals of percutaneous circulatory support systems  107
pMCS devices  107–113
right ventricular myocardial infarction  113–114
shift towards primary unloading in STEMI  114–115
therapeutic benchmark of door-to-balloon time in STEMI  107
timely reperfusion therapy  107
treatment objectives in STEMI and cardiogenic shock  107
acute coronary thrombosis, role in STEMI pathogenesis  334
acute ischemic mitral regurgitation  163
adenosine diphosphate (ADP), release by platelets  76
adenosine diphosphate (ADP) receptor blockers  75–97
antiplatelet agents  76–80
crushed ticagrelor tablets  93–94
dual antiplatelet therapy  94–95

American College of Cardiology Foundation (ACCF) guidelines  35–48, 318, 398–399
American Heart Association (AHA) guidelines  35–48, 318, 398–399
AngioJet® thrombectomy device  126–130, 141, 172, 173, 175, 182, 223
anorexic encephalography  295
anticoagulant therapy  56–57
guidelines for STEMI  46
anticoagulants in STEMI  65–73
anticoagulant protocol for PPCI patients  73
bivalirudin  66, 67, 68, 69–72
bleeding risk  70–71, 72
choice of anticoagulant  70–72
everaparin  65, 66, 68
fondaparinux  65, 66, 68, 72
guidelines for parenteral use in STEMI  40
ideal anticoagulant drug  72
risk of stent thrombosis  71–72
unfractionated heparin  65, 66, 67, 68, 69–72
anti-glycoprotein IIb/IIIa  46
anti-glycoprotein IIb/IIIa inhibitors  46
antiplatelet agents
overview  76–80
see also adenosine diphosphate (ADP) receptor blockers
antiplatelet therapy  56–57
guidelines for STEMI  46
antiplatelet therapy to support primary PCI for STEMI, guidelines  46
APEX-AMI trial  20
APPOSITION IV trial  201
ARCTIC-Interruption trial  95
artificial intelligence  372–373
aspirin (acetylsalicylic acid)  46, 56–57, 76, 77, 80, 81, 82, 83, 84, 94
ASSENT-4 trial  315
atherogenesis (plaque formation)  119–120
atherosclerosis  119
atherothrombosis  119
ATLANTIC study  87, 88, 89, 93, 294
ATOLL trial  66, 68
b balloon-expandable mesh-covered stent  201–202
bioreosorbable vascular scaffold (BVS)  202, 414–416
bivalirudin  46, 66, 67, 68, 69–72
BRAVE-4 study  67
BRIGHT study  67, 70, 71
BVS-EXAMINATION trial  202
bystander lesions see non-culprit lesion management
c CADILLAC trial  189
cangrelor  76, 77, 78, 79, 89–91
CAPITAL study  62
CAPITAL-AMI trial  316
CAPRIE trial  82
CAPTIM trial  132–133, 301
cardiac catheterization laboratory (CCL) activation  286, 287–288, 289–290
cardiogenic shock  159–168
acute ischemic mitral regurgitation  163
antiplatelet medication  162
antithrombotic medication  162
definition  159
diagnosis  159, 160
free wall rupture  163
incidence as complication of AMI  159
inotropes  164
intensive care unit treatment  164–165
interventional management  161–162
mechanical support  165–167
pathophysiology  159, 160
percutaneous mechanical support devices  165–167
prognosis  159–160
revascularization  161–162
right ventricular failure  163–164
supportive therapy  164
treatment algorithm  161
treatment of mechanical complications  162–164
vasopressors  164
ventricular septal defect  163
Cardiological Society of India (CSI)  364
cardioprotection methods in AMI  256–265
cardioprotective pathways  259
CARESS study  62
CARESS-IN-AMI trial  316
case study illustrations see illustrated STEMI procedures
CHAMPION-PCI trial  89, 90
CHAMPION-PHOENIX trial  90, 91
CHAMPION-PLATFORM trial  89, 90, 91
CHARISMA trial  83, 95
CHILL-MI study  265
China
current status of STEMI reperfusion  357–358
ischemic heart disease as cause of death  357
long delays in STEMI treatment  358
low reperfusion rate in STEMI  358
poor prognosis for STEMI  358
regional networks of STEMI care 360, 361
STEMI care program 358–361
chronic kidney disease, guidelines for use of angiography 45
CLARITY-TIMI trial 83, 84
CLASSICS trial 82
Clearway™ catheter 130
clinical trials compendium 3–27
intra-aortic balloon pump and counterpulsation 23–27
left ventricular support devices 23–27
no-reflow management 9–13
percutaneous coronary intervention in non-culprit vessel 19–22
stents 4–8
thrombectomy 14–18
clopidogrel 46, 56–57, 67, 76, 77, 78, 81–85, 86, 88, 90, 92, 94, 95
cloud computing 373
LATIN STEMI network 375–385
coagulation process, steps in 76
COBALT study 4
COCUA trial 402, 404
Combo™ stent (combined DES and EPC capture stent) 413–414
COMFORTABLE-AMI trial 196, 198
COMMIT/CCS-2 trial 83, 84–85
COMPARE-ACUTE trial 402, 404
COMPLETE trial 402, 404
computer power development 371–372
CREATE registry 363
CREDO trial 81, 82
CRISP-AMI trial 25, 107
CROSS-AMI trial 402, 404
CULPRIT-SHOCK trial 162
CURE trial 81, 82, 149
CURRENT-OASIS 7 trial 82, 84
CVLPRIT study 21, 400, 401
cyclo-pentyl-triazolo-pyrimidine (CPTP) 78, 79

D
DANAMI-2 trial 276, 300, 301
DANAMI-3 trial 402, 404
DAPT trial 94–95
DEAR-MI study 177
decision support systems 372–373
DEDICATION trial 7, 191
delayed PCI 92
DESERT Cooperation meta-analysis 191
DES-LATE trial 95
dipyridamole 76, 81
Diver CE thrombectomy device 140, 172, 174
door-to-balloon time
definition 275
early initiatives to minimize 277–278
future directions in reducing 280
institutional factors 277
key subintervals 277–278
limitations as a quality of care measure 279–280
predictor of morbidity and mortality in STEMI 275–277
prognostic value in STEMI 275–277
reducing 277–280
regional STEMI systems to further reduce 278–279
therapeutic benchmark in STEMI 107
drug-eluting stents (DES) in STEMI
first generation 190–195
second-generation 195–200
dual antiplatelet therapy 94–95, 412

e
Eliminate thrombectomy device 141, 174
emergency medical services (EMS)
cardiac catheterization laboratory (CCL)
activation 286, 287–288, 289–290
defibrillation capability 287
destination protocols 286–287
diagnosis of acute STEMI 286–287
essential roles 286–287
interhospital transfer 290–291
patient transport logistics 291–292
PH-EKG (pre-hospital electrocardiogram)
interpretation 286, 287, 288–289
pre-hospital medications 294
quality improvement in three key time intervals 292–293
STEMI with out-of-hospital cardiac arrest (OHCA) 294–295
supplemental roles 287–291
endothelial nitric oxide synthase (eNOS)-protein kinase G pathway 259
endothelial progenitor cell (EPC) capture stent 409–413
enoxaparin 46, 56–57, 65, 66, 68
eptifibatide 46, 80
antiplatelet therapy to support primary PCI for STEMI 46
classification of recommendations and levels of evidence 36–37
evaluation and management of patients with STEMI and out-of-hospital cardiac arrest 46
organizations involved 35
pace of change 35
primary percutaneous coronary interventions and STEMI 47
recommendation for angiography in patients with chronic kidney disease 45
recommendations for intensive glucose control in STEMI 44
recommendations for PCI for unprotected left main coronary artery disease 45
recommendations for the use of fractional flow reserve 45
recommendations for the use of glycoprotein IIb/IIIa receptor antagonists 38
recommendations for the use of parenteral anticoagulants 40
recommendations for the use of stents in STEMI 44
recommendations for the use of thienopyridines 39
recommendations for thrombus aspiration during PCI for STEMI 44
recommendations for triage and transfer for PCI 41–43, 48
GUSTO-1 trial 56
GUSTO-IIb study 275

h
HARMONEE study 414
healthcare disparities 374–375, 379–380
HEAT-PPCI trial 66, 69–70, 71
HELP AMI study 20
heparin, unfractionated see unfractionated heparin
Holmes, David R 333
HORIZONS-AMI trial 21, 66, 69, 70, 71, 147, 190, 194, 399
Hunter thrombectomy device 140, 172, 174

i
IABP-SHOCK trial 25, 160
IABP-SHOCK II trial 110, 167
illustrated STEMI procedures
  background information 207
  basic skills 207–221
    Case 1 208–210
    Case 2 211–212
    Case 3 213–214
    Case 4 215–218
    Case 5 219–221
complex STEMI procedures 239–254
  Case 11 240–241
  Case 12 242–245
  Case 13 246–249
  Case 14 250–251
  Case 15 252–254
Mehta strategy for treatment of thrombus in
  STEMI lesions 223–238
  thrombus management 223–238
    Case 6 224–225
    Case 7 226–229
    Case 8 230–232
    Case 9 233–235
    Case 10 236–238
Impella® devices 107, 109, 110–111, 113–114, 165, 166
India
  aims and goals for STEMI INDIA 364
  beginnings of STEMI INDIA 364
  burden of cardiovascular disease 363
  challenges of STEMI care 363
  developing a STEMI system of care 364–366
  epidemiological transition 363
  estimates of STEMI incidence 363
  involvement of the Association Physicians of
    India (API) 367
  involvement of the Cardiological Society of
    India (CSI) 367
  methods of STEMI treatment 363
  prototype statewide STEMI project
    (Tamilnadu pilot) 366–368
  public engagement and education about
    STEMI 368
  state government involvement in the STEMI
    program 367
  statewide ambulance network 367
  STEMI INDIA framework for a statewide
    STEMI program 367–368
  STEMI INDIA model 364–366
INFUSE-AMI trial 10, 136, 138, 176
inotropes 164
intensive care unit, treatment of cardiogenic
  shock 164–165
inter-hospital transfer system, organizing
  305–306
internet of things 374
intra-aortic balloon pump (IABP) and
  counterpulsation 23–27, 107, 108–110,
  113–114, 165, 167
ISAR-REACT 5 trial 96
ISAR-SHOCK study 110
ISAR-TRIPLE study 95
ISIS-2 trial 55–56
iVAC 2L* 165, 166
j
  JETSTENT trial 135–136, 137, 180, 182
l
  laser thrombectomy 174
  left main coronary artery disease, unprotected,
    guidelines for use of PCI 45
  left ventricular support devices, clinical
    trials 23–27
Los Angeles County STEMI system 302, 303
low-frequency ultrasound thrombectomy 174
low molecular weight dextran 81
low molecular weight heparin (LMWH) 76
Lumen Americas Telemedicine Infarct
  Network (LATIN) 375–376, 379,
  383–389
  ambulance networks 388–389
  creation of LATIN hubs and spokes 386–387
  methods 383–386
  network structure 383
  protocol 387–388
  results 386–389
  SINCERE database 383
  STEMI procedure 389
  telemedicine platform 388
m
  MANJUSRI study 95
  MASTER I trial 201
  MASTER II trial 201
  McCarthy, John 372
  McLuhan, Marshall 372
  MEGA® family of IABPs 108
  Mehta, Sameer 345, 364
Mehta strategy for treatment of thrombus in STEMI lesions xiii, 121–122
illustrated procedures 223–238
limitations 130–133
techniques and results 122–130
meizothrombin 76
Minneapolis Heart Institute (MHI) regional STEMI system 300–302, 308–309
mitochondria, cardioprotective pathways 259
MOJITO study 93
MORTAL study 148–149
Moscow City Center of Interventional Cardiology
patient transport time challenges in heavy traffic 335–340
use of pre-hospital systemic thrombolytic therapy (PH-TLT) 335–340
Mullasari, Ajit 364
multivessel percutaneous coronary intervention (MV-PCI) 397–398, 404–405
MUSTELA trial 135–136, 138, 176, 180
myocardial injury, measuring in the clinic 260, 261
myocardial ischemia–reperfusion injury see reperfusion injury
myocardial reperfusion, effects of 107
n
National Cardiovascular Data Registry (NCDR) 279
neoatherosclerosis, in-stent 195
networks for optimal STEMI management see regional STEMI systems of care
new technologies for STEMI interventions
bioreorbable vascular scaffold (BVS) 414–416
stents 409–416
non-culprit lesion management
areas of uncertainty 403
cardiogenic shock 402, 403
current evidence 398–401
guidelines on management 398–399
lesion instability concerns 397–398
meta-analyses 401, 402
multivessel percutaneous coronary intervention (MV-PCI) 397–398, 404–405
ongoing studies 404
percutaneous coronary intervention clinical trials 19–22
possible strategies 398
presence of ongoing ischemia 402
prospective studies 399–401
retrospective studies 399
special circumstances 401–404
unstable lesions 403, 404
nonprimary percutaneous coronary intervention 92
NORDISTEMI trial 62, 317
no-reflow management, clinical trials 9–13
North Carolina RACE system of STEMI care 302–303
NRMI-2 registry 276
NRMI-2 trial 109–110
O
OASIS-2 trial 149
OASIS-6 trial 65–66
out of hospital cardiac arrest (OHCA), STEMI complication 46, 294–295
P
P2Y12 inhibitors 77, 78
P2Y12 receptor inhibitors 57
PAMI-1 study 188
parenteral anticoagulants, guidelines for use in STEMI 40
PASEO trial 4
PASSION trial 8, 191
patient transport
logistics in emergencies 291–292
response to time challenges in urban environments 335–340
PEACE study 357, 358
PEGASUS-TIMI trial 88, 89, 94, 95
percutaneous coronary intervention in non-culprit vessel, clinical trials 19–22
percutaneous heart pump (PHP) 109
percutaneous left ventricular assist devices 167
percutaneous transluminal coronary angioplasty (PTCA) 59
adjuvant pharmacotherapy 189
use of stenting 188–189
percutaneously delivered mechanical circulatory support (pMCS) devices 107–113
pervasive computing 374
pharmacoinvasive management of STEMI 315–321
current guidelines 318
definition of pharmacoinvasive therapy 316
fibrinolytic therapy 315
guideline recommendations 318
ideal time intervals for STEMI intervention 318–321
reperfusion strategies 318–321
trials comparing therapeutic options 316–318
pharmacoinvasive strategy 60–62
PH-EKG (pre-hospital electrocardiogram) interpretation 286, 287, 288–289
QRS complex ST-elevation mimics 289
PIHRATE study 176
PIONEER-AF study 95
plaque formation (atherogenesis) 119–120
platelets and coagulation 76
PLATO study 87, 88
pocket electrocardiogram (EKG) remote monitoring system 374
PRAGUE study 299, 301
PRAGUE-2 trial 299–300
PRAGUE-13 trial 402, 404
PRAMI trial 19, 399, 400, 401
pre-hospital diagnosis and triage, comparison of three methods 389–391
pre-hospital electrocardiogram (PH-EKG) interpretation 286, 287, 288–289
QRS complex ST-elevation mimics 289
pre-hospital medications 294
pre-hospital systemic thrombolytic therapy (PH-TLT) 335–340
pre-hospital triage and management 285–295
cardiac catheterization laboratory (CCL)
activation 286, 287–288, 289–290
defibrillation capability 287
destination protocols 286–287
diagnosis of acute STEMI 286–287
emergency medical service (EMS) providers 286
emergency medical services (EMS) essential roles 286–287
emergency medical services (EMS) supplemental roles 286–291
interhospital transfer by EMS 290–291
medications 294
patient transport logistics 291–292
PH-EKG (pre-hospital electrocardiogram) interpretation 286, 287, 288–289
primary therapeutic goal of timely reperfusion 285
quality improvement in three key time intervals 292–293
STEMI receiving center (SRC) network 286–287
STEMI with out-of-hospital cardiac arrest (OHCA) 294–295
PREVENT-ICARUS trial 10
primary percutaneous coronary intervention (PPCI) 275
and STEMI, guidelines 47
comparison with thrombolytic therapy 58–59
limitations in STEMI care 315
overview of randomized clinical trials 58–59
STEMI procedure 285
STEMI process 285
time-dependency of effectiveness 275–81
PRODIGY trial 5, 95
prognosis for STEMI, influence of time to treatment 275–277
Pronto thrombectomy device 140, 172, 174
protease-activated receptor-1 (PAR-1) antagonists 80
PROTECT I trial 24
PROTECT II study 25
protein C 76
Puerto Rico Infarction National Collaborative Experience (PRINCE) 343–353
background 343–344
challenges faced by 343–344
data collection 346, 347
executing the plan 346–349
hospital door-to-balloon time reducing process 346–349, 350
motivations for change 345
pre-hospital diagnosis and triage 349–352
total ischemia time as ultimate goal 352–353

q
QuickCat thrombectomy device 140, 172, 174
radial route see transradial techniques to improve STEMI outcomes
RADIAL-AMI pilot study 146
RAPID trial 93
REDUAL-PCI study 95
REDUCE study 413–414
regional STEMI systems of care 299–312
challenges of implementing and maintaining 310–312
direct admission to the cardiac catheterization laboratory 307
education and training 307, 309–310
empower the emergency department physician 307
example level 1 STEMI protocol 308
example patient transfer datasheet 309
feedback and quality improvement 310
growth and success within the United States 300–305
individualize transfer agreements 307
key components 306–310
leadership and support 310
Los Angeles County STEMI system 302, 303
Minneapolis Heart Institute system 300–302, 308–309
North Carolina RACE system 302–303
organizing a system for inter-hospital transfer 305–306
standardized protocols 306–307, 308
to reduce door-to-balloon time 278–279
transfer for PPCI, trials 299–300
REMEDIA trial 15, 178
remote ischemic conditioning (RIC) 256–265
activation of the remote effector organ 258
alternative methods of cardioprotection 265
cardioprotective pathways 259
comedication effects 264
concept 256–258
confounding factors 263–264
effect in acute myocardial infarction 260–263
extracardiac effects of RIC 260
introducing as standard adjuvant therapy in STEMI 265
measuring myocardial injury in the clinic 260, 261
mechanisms 258–260
patients with cardiovascular risk factors 263–264
patients with comorbidities 263–264
reduction of myocardial infarct size 257–258
signal transduction of RIC in the heart 259
signal transfer from the remote effector organ to the heart 258–259
temporal variants 257
REOPEN-AMI study 10
reperfusion injury 107, 256
cardioprotection methods 256–265
clinical implications 255
definition 255
effects of reactive oxygen species 255
important consideration in AMI interventions 255, 256
remote ischemic conditioning (RIC) 256–265
reperfusion injury salvage kinase (RISK) pathway 259
reperfusion strategies in STEMI 315
reperfusion therapy, timing of rescue PCI 315
Rescue thrombectomy device 141, 173, 175, 183
RESEARCH registry 192–193
reteplase 56, 60–61
return of spontaneous circulation (ROSC) 294–295
revascularization of non-culprit lesions 398
REWARD MI study 202
RIFLE STEACS study 147
right ventricular failure 163–164
right ventricular support devices 114
Rinspirator thrombectomy system 141, 172, 173, 174, 182, 183
RIVAL study 147
secondary PCI 92
self-expanding drug-eluting stent 200–201
SESAMI trial 191
SHOCK trial 109, 113, 161, 163, 402
SIAM-III trial 62, 316
SINCERE (Single INdividual Community Experience Registry) database 121, 122, 127, 130, 138, 139, 142, 207, 210, 232, 383
sirolimus-eluting stent 409
SMART-AMI trial 136
Society for Cardiovascular Angiography and Percutaneous Coronary Interventions 35
socioeconomic disparities in cardiac risk factors 374
Sprirroflex® AngioJet device 128
staged PCI to non-culprit lesions 398
STEMI INDIA
aims and goals 364
beginnings of 364
framework for a statewide STEMI program 367–368
involvement in education and training 368
pilot Tamilnadu STEMI project 366–368
system of care model 364–366
work outside of India 368
STEMI interventions, beyond the culprit lesion 397–405
STEMI-Kovai Erode study 364
STEMI pathogenesis, role of acute coronary thrombosis 334
STEMI procedures see illustrated STEMI procedures
STEMI-RADIAL trial 147–148
STEMI receiving center (SRC) network 286–287
STEMI with out of hospital cardiac arrest (OHCA) complication 46, 294–295
Stent for Life (SFL) initiative 328–330
Stent PAMI trial 188
stent thrombosis, risk with anticoagulants 71–72
STENTIM-2 trial 189
stents in STEMI interventions 187–202
adjuvant pharmacotherapy 189
balloon-expandable mesh-covered stent 201–202
bare-metal stents 189–190
bioresorbable vascular scaffold (BVS) 202, 414–416
clinical trials 4–8
Combo™ stent (combined DES and EPC capture stent) 413–414
endothelial progenitor cell (EPC) capture stent 409–413
first drug-eluting stents (DES) in STEMI 190–195
guidelines for use in STEMI 44
historical perspective 187–188
how it all started 188–189
in-stent neoatherosclerosis 195
in-stent re-stenosis with bare metal stents 189–190
in-stent re-stenosis with drug-eluting stents 194–195
late stent thrombosis with DES 191–193
network meta-analysis 198, 201–200
new technologies 409–416
randomized trials on second-generation DES 195–196
recognition of the benefits of stenting 188–189
SCAAR data analysis 197–198
second-generation drug-eluting stents 195–200
self-expanding drug-eluting stent 200–201
stent thrombosis 193–194
STEP-PAMI study 364
STREAM trial 62, 317–318, 364
streptokinase 56, 80
survivor-activating factor enhancement (SAFE) pathway 259
Swedish Coronary Angiography and Angioplasty Register (SCAAR) 197–198
T-SEARCH registry 192–193
TandemHeart™ device 107, 109, 110–111, 112, 113–114, 165, 166
TAPAS trial 14, 135–136, 139, 173, 175, 177, 179, 232
TASTE trial 137, 139, 176, 179, 183, 232
telemedicine
applications in STEMI 371
artificial intelligence 372–373
challenges of future development 391
cloud computing 373
comparison with other pre-hospital diagnosis and triage methods 389–391
computer power development 371
decision support systems 372–373
definition 371
healthcare disparities 374–375
innovative STEMI protocols 379–391
integrated telemedicine platform 375–376
telemedicine (cont’d)
  internet of things 374
  limitations 391
  Lumen Americas Telemedicine Infarct Network (LATIN) 375–376, 379, 383–389
  opportunity to reduce healthcare disparities 379–380
  patient data privacy 371
  pervasive computing 374
  pocket electrocardiogram (EKG) remote monitoring system 374
  reducing inequalities in AMI care 381–382
  role in STEMI interventions 371–376
  socioeconomic disparities in cardiac risk factors 374
  time as a strong predictor of outcomes 375
  ubiquitous computing 374
  where ambulance services for AMI are poor or lacking 380–381
  TEMPURA study 146
  tenecteplase (TNK) 56
  therapeutic hypothermia devices 295
  thienopyridines 39, 46, 78–79, 94
  thrombectomy
    clinical trials 14–18
    evidence for manual thrombectomy 173, 175–179, 183
    evidence for mechanical thrombectomy 179–183
    global strategies and recent results 133–39
    Mehta strategy 121–133
    rationale for use in acute myocardial infarction 171
    recommendations for the use of manual thrombectomy devices 175
    strategy related to thrombus grade 121
    thrombectomy devices 140–141, 171–173, 174–175
  thrombin inhibitors 76
  thrombolytic agents, clinical benefits, risks and contraindications 55–57
  thrombolytic therapy
    absolute contraindications 58
    clinical benefits, risks and contraindications for thrombolytic agents 55–57
    facilitated PCI 60–62
    randomized clinical trials 58–59
    relative contraindications 58
    risks 57–58
    role in STEMI 55–62
    time dependent benefits 59–60, 61
    thrombus and STEMI 120–121
    thrombus aspiration during PCI for STEMI, guidelines 44
    thrombus in myocardial infarction (TIMI) thrombus grade 121
    thrombus management for STEMI interventions 119–142
    illustrated STEMI procedures 223–238
    Mehta strategy 121–133
    red thrombus formation 120
    thrombectomy strategy related to thrombus grade 121
    thrombus burden 121
    thrombus dynamic pathophysiology 120–121
    thrombus grade 121
    thrombus pathophysiology 119–120
    white thrombus formation 120
    thrombus risk factors 119
    Thrombuster thrombectomy device 140, 172, 174
    ThromCat® 130
    ticagrelor 46, 71, 76, 77, 78, 79, 87–89, 92–95
    ticlopidine 76, 77, 78, 81, 82
    time to reperfusion, clinical impact 59–60, 61
    time to treatment
      influence on PPCI effectiveness 275–277
      influence on STEMI prognosis 275–277
      strong predictor of outcomes 375
    tirofiban 46, 80
    tissue factor, role in coagulation 120
    tissue plasminogen activator (tPA) 56, 58
    TOTAL trial 138, 139, 176, 179, 183, 232
    TRANSFER study 62
    TRANSFER-AMI trial 316
    transradial techniques to improve STEMI outcomes 145–155
    bleeding avoidance strategy for primary PCI 148–150
    body of evidence (studies) 145–148
    developing a transradial AMI program 150–154
    economic benefits 150
    European Society of Cardiology guidelines 155
historical perspective 145
limitations 154
quality of life benefits 150
rationale for using 148–150
triage and transfer for percutaneous coronary intervention 48
guidelines 41–43
TRILOGY ACS trial 85, 86
TRITON-TIMI trial 85, 86, 92
TRIUMPH SHOCK trial 160
TROFI study 176
TVAC thrombectomy device 141, 173, 175, 183
TWILIGHT trial 96
TYPHOON trial 190–191

u
ubiquitous computing 374
unfractionated heparin (UFH) 46, 56–57, 65, 66, 67, 68, 69–72, 76, 81
unprotected left main coronary artery disease, guidelines for use of PCI 45
urban combined pharmacoinvasive management of STEMI 335–340

v
vacuum aspiration thrombectomy devices 183
VAMPIRE study 180, 183
vasopressors 164
Vein Graft Angiojet Study 2 128
venoarterial extracorporeal membrane oxygenation (VA-ECMO) 107, 109, 110–111, 112–114
ventricular septal defect 163
VMAX thrombectomy device 172, 174
vorapaxar 76, 80

w
warfarin 76
WEST trial 62, 317
WOEST study 95

x
X-AMINE ST study 181, 182
X-sizer® thrombectomy device 130, 141, 172, 173, 174, 182
Xa inhibitors 76
Xtract thrombectomy device 141